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BIRC3 is a recurrently mutated gene in chronic lymphocytic leukemia(CLL) but the functional implications of BIRC3 mutations are largelyunexplored. Furthermore, little is known about the prognostic impact
of BIRC3 mutations in CLL cohorts homogeneously treated with first-line
fludarabine, cyclophosphamide, and rituximab (FCR). By immunoblotting
analysis, we showed that the non-canonical nuclear factor-κB pathway is
active in BIRC3-mutated cell lines and in primary CLL samples, as docu-
mented by the stabilization of MAP3K14 and by the nuclear localization of
p52. In addition, BIRC3-mutated primary CLL cells are less sensitive to flu-
darabine. In order to confirm in patients that BIRC3mutations confer resist-
ance to fludarabine-based chemoimmunotherapy, a retrospective multicen-
ter cohort of 287 untreated patients receiving first-line FCR was analyzed
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ABSTRACT
BIRC3 mutations in CLL
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Introduction
Nuclear factor-κB (NF-κB) signaling is a key component
of the development and evolution of chronic lymphocytic
leukemia (CLL).1 Two NF-κB pathways exist, namely the
canonical and non-canonical pathways.2 The former is
triggered by B-cell receptor signaling via Bruton tyrosine
kinase (BTK), while the latter is activated by members of
the tumor necrosis factor (TNF) cytokine family.3 Upon
receptor binding, the TRAF3/MAP3K14-TRAF2/BIRC3
negative regulatory complex of non-canonical NF-κB sig-
naling is disrupted, MAP3K14 (also known as NIK), the
central activating kinase of the pathway, is released and
activated to induce the phosphorylation and proteasomal
processing of p100, thereby leading to the formation of
p52-containing NF-κB dimers. The p52 protein dimerizes
with RelB to translocate into the nucleus, where it regu-
lates gene transcription. BIRC3 (Baculoviral IAP Repeat
Containing 3) is a negative regulator of non-canonical NF-
κB. Physiologically, BIRC3 (also known as cIAP2) cat-
alyzes MAP3K14 protein ubiquitination in a manner that
is dependent on the E3 ubiquitinine ligase activity of its C-
terminal RING domain. MAP3K14 ubiquitination results
in its proteasomal degradation.4
B-cell neoplasia often pirates signaling pathways by
molecular lesions to promote survival and proliferation.
Although according to bioinformatics criteria BIRC3 is one
of the candidate driver genes of CLL, the functional impli-
cations of BIRC3 mutations are partially unexplored.5-7
Furthermore, little is known about the prognostic impact
of BIRC3mutations in CLL cohorts homogeneously treat-
ed first-line with fludarabine, cyclophosphamide, and rit-
uximab (FCR).7
FCR is the most effective chemoimmunotherapy regi-
men for the management of CLL in young and fit patients
devoid of TP53 disruption.8 Survival after FCR is, howev-
er, variable, and is affected by the molecular characteris-
tics of the CLL clone.9 Deletion of 17p and TP53mutations
are present in most, but not all patients who are refractory
to chemo-immunotherapy, which prompts the identifica-
tion of additional biomarkers associated with early failure
of FCR.10-12 
Methods
Functional studies
The human CLL cell line MEC1, the splenic marginal zone lym-
phoma cell lines SSK41 and VL51, the mantle cell lymphoma cell
lines MAVER-1, Z-138 and JEKO-1, the human HEK-293T cell line,
as well as primary CLL cells were used in functional experiments.
The entire non-canonical NF-κB pathway was assessed by western
blot analysis. Quantitative real-time polymerase chain reaction
(qRT-PCR) was utilized to analyze the non-canonical NF-κB signa-
ture. Primary CLL were exposed to fludarabine and venetoclax for
24-48 h and apoptosis was measured using the eBioscience
Annexin V Apoptosis Detection Kit APC (ThermoFisher). Details
are supplied in the Online Supplementary Methods.
Cancer personalized profiling by deep sequencing
A retrospective multicenter cohort of 287 untreated CLL
patients receiving first-line therapy with FCR was analyzed for
mutations, including 173 patients from a previously published
multicenter clinical series and 114 new patients not included in our
previous report.10 The study was approved by the Ethical
Committee of the Ospedale Maggiore della Carità di Novara asso-
ciated with the Amedeo Avogadro University of Eastern Piedmont
(study number CE 67/14). Further information is provided in the
Online Supplementary Methods. A targeted resequencing gene panel
was designed to include: (i) coding exons plus splice site of 24
genes known to be implicated in CLL pathogenesis and/or prog-
nosis; (ii) 3’UTR of NOTCH1; and (iii) enhancer and promoter
region of PAX5 (size of the target region: 66627bp) (Table S1).6,7
The next-generation sequencing libraries for genomic DNA
(gDNA) were constructed using the KAPA Library Preparation Kit
(Kapa Biosystems) and those for RNA were constructed using the
RNA Hyper Kit (Roche). Multiplexed libraries (n=10 per run) were
sequenced using 300-bp paired-end runs on a MiSeq sequencer
(Illumina) to obtain a coverage of at least 2000x in >90% of the tar-
get region (66627 bp) in 80% of cases (Online Supplementary Table
S2). A robust and previously validated bioinformatics pipeline was
used for variant calling (Online Supplementary Appendix).
Statistical analysis
Progression-free survival (PFS) was the primary endpoint.
Survival analysis was performed with the Kaplan-Meier method
and compared between strata using the log-rank test. To account
for multiple testing, adjusted P values were calculated using the
Bonferroni correction. The adjusted association between exposure
variables and PFS was estimated by Cox regression. Internal vali-
dation of the multivariate analysis was performed using a boot-
strap approach. Statistical significance was defined as a P value
<0.05 (Online Supplementary Appendix).
Results
BIRC3 mutations associate with activation 
of non-canonical nuclear factor-κB signaling  
In order to map unique BIRC3 mutations in CLL com-
prehensively, we compiled somatically confirmed variants
identified in the current CLL study cohort with those
identified in previous studies13 or listed in public CLL
mutation catalogues (Figure 1A). Virtually all BIRC3muta-
tions were frameshift mutations or stop codons clustering
in two hotspot regions comprised between amino acids
by targeted next-generation sequencing of 24 recurrently mutated genes in CLL. By univariate analysis
adjusted for multiple comparisons BIRC3mutations identify a poor prognostic subgroup of patients in whom
FCR treatment fails (median progression-free survival: 2.2 years, P<0.001) similar to cases harboring TP53
mutations (median progression-free survival: 2.6 years, P<0.0001). BIRC3 mutations maintained an inde-
pendent association with an increased risk of progression with a hazard ratio of 2.8 (95% confidence interval
1.4-5.6, P=0.004) in multivariate analysis adjusted for TP53mutation, 17p deletion and IGHVmutation sta-
tus. If validated, BIRC3 mutations may be used as a new molecular predictor to select high-risk patients for
novel frontline therapeutic approaches.
367-438 and amino acids 537-564. BIRC3 variants were
predicted to generate aberrant truncated transcripts caus-
ing the elimination or truncation of the C-terminal RING
domain of the BIRC3 protein. The RING domain of
BIRC3 harbors the E3 ubiquitin ligase activity that is
essential for proteasomal degradation of MAP3K14, the
central activating kinase of non-canonical NF-κB signaling.
This observation points to non-canonical NF-κB activation
F. Diop et al.
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Figure 1. The non-canonical nuclear
factor-κB pathway is active in BIRC3-
mutated chronic lymphocytic leukemia
cell lines and primary samples. (A)
Disposition of BIRC3 mutations across
the protein. The mutations identified by
Landau et al.6, Puente et al.7 and from a
public CLL mutation catalogue (COSMIC
v85) are plotted in gray. Individual
BIRC3 mutations identified in the cur-
rent studied cohort and in our previous
study13 are plotted in red. (B) Western
blot analysis of BIRC3 protein expres-
sion and NF-κB2 activation and process-
ing in the splenic marginal zone lym-
phoma (SMZL) cell lines SSK41, VL51
and in the chronic lymphocytic leukemia
(CLL) cell line MEC1, carrying wildtype
(wt) or disrupted BIRC3. The MAVER-1
and Z-138 cell lines were used as posi-
tive controls of non-canonical NF-κB
activation, harboring genetic activation
of non-canonical NF-κB signaling. The
JEKO-1 and HEK 293T cell lines were
used as negative controls for non-
canonical NF-κB signaling. α-actin was
used as a loading control. Color codes
indicate the gene status in each cell
line. The aberrant BIRC3 band
expressed in MEC1 and VL51 cell lines
corresponds in size to the predicted
BIRC3-truncated protein, encoded by
the mutant allele. (C) Western blot
analysis showing BIRC3 expression and
NF-κB2 processing in purified primary
tumor cells from five CLL and SMZL
patients carrying wildtype or disrupted
BIRC3. Color codes indicate the gene
status in each cell line. The aberrant
BIRC3 bands in patients 09321, 14462
and 12603 correspond in size to the
predicted BIRC3-truncated protein
encoded by the mutant allele. α-actin
was used as a loading control. (D)
Western blot of whole cell extract, cyto-
plasmic or nuclear fractions of the
SMZL and CLL cell lines probed for the
NF-κB2 subunits p100 and p52. The
MAVER-1 and Z-138 cell lines served as
positive controls while the JEKO-1 and
HEK 293T cell lines were used as nega-
tive controls. β-tubulin and BRG1
served as controls for the purity of the
cytoplasmic and nuclear fractionations,
respectively. (E) Gene set enrichment
analysis score and distribution of non-
canonical NF-κB target genes along the
rank of transcripts differentially
expressed in the SMZL cell lines SSK41,
VL51 and in the CLL cell line MEC1. The
JEKO-1 cell line was used as a negative
control. (F) Validation of expression of
non-canonical NF-κB target genes in the
same SMZL and CLL cell lines as deter-
mined by quantitative real-time poly-
merase chain reaction analysis.
Changes of gene expression were nor-
malized to GAPDH expression; relative
quantities were log2 normalized to con-
trol samples (the mantle cell lymphoma
cell line, JEKO-1).
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through MAP3K14 stabilization as the predicted function-
al consequence of BIRC3 mutations in CLL.  
The non-canonical NF-κB signaling was profiled by
immunoblotting in B-cell tumor cell lines and primary CLL
cells with different genetic make-up in the non-canonical
NF-κB pathway to verify whether BIRC3 mutations lead
to constitutive non-canonical NF-κB activation. Additional
genetic features of the above-mentioned cell lines and pri-
mary CLL cells are shown in Online Supplementary Table
S3.  In the VL51 splenic marginal zone lymphoma cell line
and in the MEC1 CLL cell lines, both harboring endoge-
nous truncating mutations of the BIRC3 gene, non-canon-
ical NF-κB signaling was constitutively active, as docu-
mented by the stabilization of MAP3K14, phosphoryla-
tion of NF-κB2, its processing from p100 to p52, as well as
the nuclear localization of p52 (Figure 1B-D). Consistent
with the biochemical clues of non-canonical NF-κB activa-
tion, the gene expression signature of the VL51 and MEC1
cell lines was significantly enriched in non-canonical NF-
κB target genes (Figure 1E, F). Non-canonical NF-κB signal-
ing in BIRC3-mutated cells was consistent with that in
mantle cell lymphoma cell lines known to harbor a dis-
rupted TRAF3/MAP3K14-TRAF2/BIRC3 negative regula-
tory complex by loss of TRAF3 or TRAF2.14 Like BIRC3-
mutated cell lines, primary CLL samples harboring inacti-
vating mutations of BIRC3 also showed stabilization of
MAP3K14 and NF-κB2 processing from p100 to p52 (Figure
1C), thus confirming that non-canonical NF-κB activation
is also a feature of primary cells harboring BIRC3 variants.
MAP3K14 stabilization is largely associated with BIRC3
mutations. Indeed all seven cases harboring non-canonical
NF-κB genetic lesions showed either a strong or a slight
MAP3K14 band, while, conversely, only one out of five
cases lacking a non-canonical NF-κB lesion had MAP3K14
expression (Fisher exact test, P=0.01).
MAP3K14 was genetically targeted by shRNA to test
whether BIRC3-mutated cells are addicted to its stabiliza-
tion. Compared to non-targeting shRNA, the most effi-
cient anti-MAP3K14 shRNA-D resulted in a partial silenc-
ing of MAP3K14 and in decreased NF-κB2 processing from
p100 to p52. This translated into a reduced cell viability of
the BIRC3-mutated VL51 cell line transduced with
shRNA-D. This observation indicates that MAP3K14 sta-
bilization is a vulnerability of BIRC3-mutated cells (Figure
2). In order to test the contribution of BTK to non-canon-
ical NF-κB signaling when it is activated through BIRC3
mutations, BIRC3-mutated cell lines, as well as cell lines
harboring a disrupted or competent TRAF3/MAP3K14-
TRAF2/BIRC3 negative regulatory complex were treated
with ibrutinib at different dosages and non-canonical NF-
κB signaling activation was probed by immunoblotting of
the NF-κB2 processing from p100 to p52. Processing from
p100 to p52 was unaffected by ibrutinib treatment in cell
lines harboring BIRC3 mutations (Figure 3) or a disrupted
TRAF3/MAP3K14-TRAF2/BIRC3 negative regulatory
complex, consistent with the notion that BIRC3mutations
activate non-canonical NF-κB by bypassing BTK blockade
by ibrutinib.14
BIRC3 mutations confer resistance to fludarabine
in primary chronic lymphocytic leukemia cells 
We performed in vitro pharmacological studies on pri-
mary CLL cells to verify the vulnerabilities of BIRC3-
mutated cells. CLL cells purified from patients carrying
BIRC3 mutations were treated with increasing doses of
fludarabine. Drug-induced apoptosis was compared to
that of samples harboring TP53 mutations, which repre-
sent a control for fludarabine resistance. CLL cells devoid
of genetic lesions in either BIRC3 or TP53 were used as a
control for fludarabine sensitivity. The molecular charac-
teristic of the ex-vivo CLL cells are listed in Online
Supplementary Table S4.
BIRC3-mutated cells showed delayed fludarabine-
induced cell death, as no response was observed after 24 h
of treatment, at variance with TP53- and BIRC3-wildtype
samples. At this time point, cell viability curves of BIRC3-
mutated samples overlapped almost completely with
those of TP53-disrupted samples, which are known to be
fludarabine resistant (Figure 4A). At 48 h, the viability of
BIRC3-mutated cells was lower than that of TP53-mutat-
ed samples, but higher than that of TP53- and BIRC3-wild-
type samples (Figure 4B). 
BIRC3 mutations in CLL
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Figure 2. Knockdown of MAP3K14 by RNA interference in VL51 cells. (A) Western blot analysis for MAP3K14 expression and for NF-κB2 processing of p100 to p52.
(B) VL51 cell viability assessed by trypan blue after transduction with lentiviral vectors expressing the shRNA-D_MAP3K14 (shD: in red), a scrambled shRNA (scram-
bled: in blue), and in non-transfected cells (CTRL: in green).
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In order to assess whether BIRC3 mutations interfere
with apoptosis, primary CLL cells were treated with vene-
toclax. Venetoclax treatment resulted in a similar reduc-
tion of cell viability in BIRC3-mutated cells, TP53-mutated
cells and BIRC3/TP53-wildtype cells (Figure 4C, D). Such
divergent sensitivity to fludarabine and venetoclax of
BIRC3-mutated CLL cells indirectly suggests that BIRC3
mutations likely affect the upstream DNA damage
response pathway rather than downstream apoptosis as a
mechanism of inducing cell death.
Patients harboring BIRC3 mutations are at risk 
of FCR failure
In order to confirm in vivo in patients that BIRC3 muta-
tions confer resistance to fludarabine-based chemoim-
munotherapy, we correlated the BIRC3 mutation status
with PFS of CLL patients treated with FCR. Mutational
profiling was performed in 287 patients who received
first-line FCR. The baseline features of the study cohort
were consistent with progressive, previously untreated
CLL (Table 1). The median follow-up was 6.8 years, with
a median PFS and overall survival of 4.6 and 11.7 years,
respectively (Table 1) consistent with observations in
clinical trial cohorts.15 As expected, SF3B1 and NOTCH1
were the most frequently mutated genes identified in
13.9% and in 13.6% of patients, respectively, followed
by TP53 in 9.4% and ATM in 6.9% of patients. BIRC3
was mutated in 3.1% of patients, reflecting the data
reported in previous studies.6,7,13 Overall, 154/287
(53.6%) cases harbored at least one non-synonymous
somatic mutation in one of the 24 CLL genes included in
our panel (range, 1-5 mutation per patient), which is con-
sistent with the typical mutational spectrum of CLL
requiring first-line treatment (Figure 5, Online
Supplementary Table S5).6,7,16
By univariate analysis adjusted for multiple compar-
isons, among the genes analyzed in our panel, only TP53
mutations (median PFS of 2.6 years; P<0.0001) and
BIRC3 mutations (median PFS of 2.2 years; P<0.001)
(Figure 6A) were associated with significantly shorter
PFS (Table 2). Following FCR treatment, the PFS of
BIRC3-mutated patients was similar to that of cases har-
F. Diop et al.
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Figure 3. The non-canonical nuclear factor-κB pathway is not switched off by ibrutinib in BIRC3-mutated cell lines. Western blot showing p100/p52 expression in
(A) MEC1 and (B) VL51 cell lines that harbor BIRC3 mutations. (C) MAVER-1 and (D) Z-138 cell lines, known to be affected by non-canonical NF-κB pathway gene
mutations and resistant to ibrutinib were used as positive controls. (E) The JEKO-1 cell line, known to be devoid of NF-κB pathway gene mutations and sensitive to
ibrutinib, was used as a negative control.  All cell lines were treated with different concentrations of ibrutinib for 72 and 96 h. DMSO: dimethylsulfoxide.
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boring TP53 disruption (Figure 6B). Consistently, BIRC3-
mutated patients had a lower likelihood of achieving
complete response (22.2%) at the end of FCR compared
to BIRC3-wildtype cases (76.7%; P=0.001). Well-known
molecular prognostic biomarkers of CLL, such as unmu-
tated IGHV gene status and 17p deletion also associated
with a significantly shorter PFS, supporting the represen-
tativeness of the study cohort (Table 2). By multivariate
analysis including variables showing a multiplicity-
adjusted significant association with PFS, BIRC3 muta-
tions maintained an independent association with PFS,
with a hazard ratio of 2.8 (95% confidence interval: 1.4-
5.6; P=0.004) (Table 2).
Discussion
The results of this study provide evidence that: (i) BIRC3
mutations are associated with activation of the non-
canonical NF-κB pathway and with resistance to fludara-
bine in vitro; and (ii) BIRC3-mutated patients, like cases
harboring TP53 disruption, are subject to failure of FCR
chemoimmunotherapy.
The mere presence of somatic mutations is insufficient
to implicate a gene in cancer. Cancer geneticists and bioin-
formaticians differentiate “passenger” events, likely being
randomly acquired, to distinguish them from mutations
targeting candidate “cancer-driver” genes, likely implicat-
ed in the tumor biology, according to a statistical defini-
tion. Any given gene is labeled as a candidate “cancer driv-
er” if it harbors somatic point mutations at a statistically
significant rate or pattern in cancer samples. In CLL, more
than 40 genes fulfill the statistical definition of a candidate
“cancer driver”, including BIRC3, but few of them are bio-
logically validated (i.e. SF3B1, NOTCH1, TP53, ATM,
FBXW7).6,7,17-20 The BIRC3 gene codes for a protein that
ubiquitinates and negatively regulates the central activat-
ing kinase of the non-canonical NF-κB pathway, namely
MAP3K14 (also known as NIK).21,22 In lymphoid malignan-
cies, the NF-κB pathway is a pivotal and positive mediator
of cell proliferation and survival.5,23,24 With regards to CLL,
BIRC3 mutations are absent in patients with monoclonal
B-cell lymphocytosis, are rare at the time of diagnosis (3-
4%), but are detectable in approximately 25% of fludara-
bine-refractory patients.13 In this study, we verified the
biological consequences of BIRC3 mutations, showing
that they are associated with activation of the non-canon-
ical NF-κB pathway, that BIRC3-mutated lymphoid cells
BIRC3 mutations in CLL
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Figure 4. Responses of primary cells lines to fludarabine and venetoclax. (A-D) Viability of BIRC3-mutated  (n=6 patients, red line), TP53-mutated (n=8 patients,
black line) and wildtype (n=7 patients, blue line) primary CLL cells treated with different concentrations of fludarabine for 24 h (A) and 48 h (B) or venetoclax for 24
h (C) and 48 h (D). The pairwise P values are listed in the tables below the respective figures. M, mutated; WT, wildtype; NT, not treated. 
A B
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are addicted to the non-canonical NF-κB pathway, and
that BIRC3-mutated CLL are resistant to fludarabine both
in vitro and in patients. It still remains to be clarified
whether NF-κB activation is the only molecular pathway
that causes chemo-refractoriness in BIRC3-mutated CLL
or whether other mechanisms are also involved.24-29
F. Diop et al.
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Table 1. Clinical data of FCR-treated chronic lymphocytic leukemia  patients according to BIRC3 mutational status.
Characteristics                                   Total                     Number of patients (%)              BIRC3 mutated patients (%)        BIRC3 wildtype patients (%)
Male                                                             N=287                                   198 (69.0%)                                               5 (55.6%)                                             193 (69.4%)
Female                                                                                                        89 (31.0%)                                                  4 (44.4)                                                85 (30.6%)
Binet A                                                         N=287                                    33 (11.5%)                                                1 (11.1%)                                              32 (11.5%)
Binet B-C                                                                                                   254 (88.5%)                                               8 (88.9%)                                             246 (88.5%)
IGHVmutated                                           N=280                                   100 (35.7%)                                                  0 (0%)                                               100 (36.0%)
IGHV unmutated                                                                                      180 (64.3%)                                                9 (100%)                                             171 (61.5%)
17p deletion                                               N=274                                     13 (4.7%)                                                    0 (0%)                                                  13 (4.7%)
No 17p deletion                                                                                        261 (95.3%)                                                9 (100%)                                             252 (90.6%)
11q deletion                                               N=273                                    47 (17.2%)                                                5 (55.6%)                                              42 (15.1%)
No 11q deletion                                                                                        226 (82.8%)                                                 4 (44.4)                                               222 (79.9%)
13q deletion                                               N=273                                   111 (40.7%)                                               3 (33.3%)                                             108 (38.8%)
No 13q deletion                                                                                        162 (50.3%)                                               6 (66.6%)                                             156 (56.1%)
Trisomy 12                                                  N=272                                    50 (18.4%)                                                4 (44.4%)                                              46 (16.5%)
No trisomy 12                                                                                           222 (81.6%)                                               5 (55.6%)                                             217 (78.1%)
Median follow-up (years)                                                                            6.8
Median PFS  (years)                                                                                       4.6
PFS % (7 years)                                                                                           31.0%
Median OS (years)                                                                                         11.7
OS % (7 years)                                                                                             75.5%
Figure 5. Mutational profile of the FCR-treated cohort. Case-level mutational profiles of 287 patients treated with FCR (fludarabine, cyclophosphamide, rituximab).
Each column represents one tumor sample, each row represents one gene. The fraction of tumors with mutations in each gene is plotted on the right. The number
and type of mutations in each patient are plotted above the heatmap. Mutations are highlighted in red. IGHV mutational status, 17p deletion and 11q deletion are
plotted at the bottom of the heatmap.
PFS: progression-free survival; OS: overall survival; IGHV: immunoglobulin
heavy variable gene.
The introduction of FCR was a breakthrough in the man-
agement of young, fit CLL patients, leading to improve-
ments in both PFS and overall survival compared to those
achieved with previous treatment regimens. In both clinical
trials and real-life cohorts,10-12 IGHV mutation status and
TP53 disruption emerged as strong predictors of poor
response to FCR. However, these molecular biomarkers do
not fully capture all high-risk patients destined to relapse.
We propose BIRC3 mutations as a new biomarker for the
identification of patients at high risk of FCR failure,  simi-
larly to cases harboring TP53 disruption. If validated in
independent series, BIRC3mutations may turn out as a new
molecular predictor of FCR resistance that could be used to
select patients to be treated with novel targeted agents. 
Table 2. Univariate and multivariate analyses of progression-free survival.
                                       Univariate analysis                                      Multivariate analysis  Internal bootstrapping validation
Characteristics          7-y PFS       Median       95% CI                P               P*                HR      LCI     UCI              P               HR    LCI      UCI       Bootstrapping
                                     (%)            PFS (y)                                                                                                                                                                   selection (%)
Binet A                             40.3%                4.5             2.4-6.6                 0.356                  -                        -             -           -                    -                     -          -            -                        -
Binet B-C                         30.0%                4.6             3.8-5.4                                                                      -             -           -                                           -          -            -                        
IGHVmutated                49.3%                6.5             3.8-9.2                <0.001            0.003                   -             -           -                0.001                -          -            -                   98.8%
IGHV unmutated           23.0%                3.9             3.5-4.4                                                                   1.8         1.3       2.6                                      1.9      1.3        2.7                       
No 11q deletion             33.4%                5.0             4.2-5.9                 0.025              0.700                    -             -           -                    -                     -          -            -                        -
11q deletion                    13.9%                3.6             2.4-4.9                                                                      -             -           -                                           -          -            -                        
No 17p deletion             33.0%                4.8             4.1-5.6               <0.0001         <0.0001                -             -           -              <0.0001             -          -            -                   99.5%
17p deletion                       nr                   1.1               0-2.6                                                                     4.0         2.2       7.5                                      4.9      2.5        9.8                       
TP53 wildtype                 33.8%                5.4             4.3-5.8               <0.0001          <0.001                   -             -           -                0.030                 -          -            -                   73.3%
TP53mutated                    nr                   2.8             2.0-3.5                                                                    1.7         1.1       2.8                                       1.8       1.1          3                        
BIRC3 wildtype              32.2%                4.8             4.1-5.6                <0.001            0.005                   -             -           -                0.004                -          -            -                   91.1%
BIRC3mutated                  nr                   2.2             0.9-3.5                                                                   2.8         1.4       5.6                                      3.4      1.6        7.3                       
EGR2 wildtype               31.5%                4.7             3.9-5.4                 0.015              0.420                    -             -           -                    -                     -          -            -                        -
EGR2mutated                   nr                   1.5               0-3.8                                                                       -             -           -                                           -          -            -                        
ATM wildtype                 32.5%                4.8             4.1-5.6                 0.029              0.812                   -             -           -                    -                    -          -            -                        -
ATMmutated                     nr                   3.2             2.4-4.1                                                                    -             -           -                                         -          -            -                        
y: year;  P: P-value; P*: Bonferroni correction; PFS: progression-free survival; CI: confidence interval; HR: hazard ratio; LCI: lower boundary of the confidence interval; UCI: upper boundary
of the confidence interval; IGHV: immunoglobulin heavy variable gene; nr: not reached.
Figure 6. Kaplan-Meier estimates of progression-free survival in BIRC3-mutated patients. (A) Cases harboring BIRC3 mutations are represented by the red line.
BIRC3-wildtype cases are represented by the blue line. (B) Cases harboring BIRC3 mutations are represented by the red line. Cases harboring TP53 disruption
(including TP53 mutation and/or 17p deletion) are represented by the yellow line. Patients devoid of BIRC3 mutation and TP53 disruption are represented by the
blue line.
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Non-canonical NF-κB activation by BIRC3 mutations
bypasses the block of BTK by ibrutinib. Consistently, NF-
κB activation and cell survival are unaffected by ibrutinib
in both CLL cells (our study) and mantle cell lymphoma
cells.14 If this preclinical evidence is validated in ibrutinib-
treated patients, BIRC3 mutations may also translate into
a biomarker for informing selection of novel agents. 
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